Phase 4Completed

Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial (Optimize@Home)

Optimization of Albuminuria-Lowering Therapies for Individual Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Pilot Remote Clinical Trial.

Sponsor
University Medical Center Groningen (Academic or other)
Enrollment
12 enrolled
Conditions
Diabetes Mellitus Type 2 With Proteinuria; Diabetes Mellitus, Type 2; Diabetes Mellitus; Diabetes; Diabetes Complications; Albuminuria; Chronic Kidney Diseases; Chronic Kidney Disease Due to Type 2 Diabetes Mellitus; Chronic Kidney Disease stage3; Chronic Kidney Disease stage4; CKD; CKD Stage 3
Interventions
Empagliflozin 10 MG; Finerenone; Withings BPM Connect; Withings Body; PeeSpot Urine Collection Device; Hem-Col Capillary Blood Collection Device; Questionnaire: participants' perspectives toward the feasibility of participation in a trial at home with digital technologies
Ages
adults, older adults
Registry
NCT06094920

Full record on ClinicalTrials.gov

From the registry

The goal of this clinical trial is to determine the feasibility of remote clinical trial conduct in patients with type 2 diabetes and elevated albuminuria. The main questions it aims to answer are: * What is the feasibility (and advantages) of remote clinical trial conduct with multiple medications in patients with type 2 diabetes and elevated albuminuria? * What is the individual response to the SGLT2 inhibitor empagliflozin in urine albumin-creatinine ratio? * What is the individual response to the SGLT2 inhibitor empagliflozin in systolic blood pressure, body weight, eGFR, and fasting plasma glucose? * Can suboptimal treatment responses to empagliflozin be overcome by the addition or substitution with finerenone? Participants will collect all study data in the comfort of their own environments * First-morning void urine samples * Capillary blood samples * Blood pressure * Body weight Participants will be assigned to a 3-week treatment period with empagliflozin 10 mg/day. Based on the albuminuria response after 2 weeks, participants will be allocated to one of three treatment…

Primary outcomes

  • Questionnaire results
  • Remote urine collection
  • Remote blood pressure measurements
  • Remote body weight measurements

History

  1. Last registry update

  2. Primary completion

  3. Started

  4. Registered

Papers citing this trial